Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2020 16h02 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients Announces Next Steps in Development Program for Lead Product Candidate Ended Quarter with $21.9...
19 oct. 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D....
24 sept. 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the...
11 sept. 2020 08h30 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C....
10 sept. 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial

CHARLOTTESVILLE, Va., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the...
08 sept. 2020 16h02 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who...
01 sept. 2020 16h02 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors

CHARLOTTESVILLE, Va., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for...
10 août 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
27 juil. 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

Guidance being incorporated into global study protocolEnrollment of first patient now expected in August CHARLOTTESVILLE, Va., July 27, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc....
07 juil. 2020 08h00 HE | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC

Phase 1b dosing expected to begin this month Data read-out expected later this quarter CHARLOTTESVILLE, Va., July 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)...

Page précédente